Global Marine Energy Market Analysis to 2020 - Capacity, Generation, Regulation and Market Share Analysis Vijaya 11.5606
GBI Research indicates that the global urological disorders market has been one of the fastest growing markets in the pharmaceutical industry. However, the market growth is expected to slow down in the future due to various restraints such as the expiry of key drugs ’ patents across all disease segments, entry of generic, and decreased annual cost of therapy in major markets such as the US, Japan and the top five countries in Europe. Nevertheless, the global urological disorders market is still forecast to grow at a moderate rate in the future.
For further details, please click or add the below link to your browser:
In 2009, the global urological disorders market was estimated to be worth $7.9 billion, representing a cumulative annual growth rate (CAGR) of 9.6% between 2001 and 2009. The market is forecast to reach $9.8 billion by 2016, indicating a CAGR of 3.1% between 2009 and 2016. The primary reason for the reduced growth rate is the patent expiries of major blockbusters, which subsequently is expected to decline the annual cost of therapy after 2009. The global urological disorders market is expected to witness a series of patent expiries between 2009 and 2016, which includes most of the top selling blockbuster drugs in the Urinary Incontinence (UI), Benign Prostatic Hyperplasia (BPH) and Urinary Tract Infections (UTI) market. The major drugs that are set to lose patent protection include Flomax (2009), Levaquin (2010), Uroxatral – in US (2011), Detrol (2012), Avodart (2015), Enablex (2015) and Ditropan XL (2015). All these drugs together account for more than $6.3 billion of revenues in the global urological disorders market. The current urological disorders pipeline does offer some promising novel products. However, the revenues generated from these products are not expected to completely make up for the revenues lost due to patent expiries. Thus, the overall market growth of the global urological disorders market is expected to decline during the forecast period.
GBI Research, the leading business intelligence provider, has released its latest research, “ The Future of Urological Disorders Therapeutics to 2016 - Increasing awareness and aging population will drive Benign Prostatic Hyperplasia and Urinary Incontinence Markets ” . It provides in-depth analysis of the unmet needs, drivers and barriers that affect the global urological disorders therapeutics market. The report analyzes the markets for urological disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales value and annual cost of therapy are forecast until 2016 for key geographies in the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers and acquisitions (M&A) and licensing agreements that shape the global markets.
For further details, please click or add the below link to your browser:
Visit our report store: http://www.gbiresearch.com
For more details contact:
info@gbiresearch.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782
Add this page to your favorite Social Bookmarking websites
